A detailed history of Hohimer Wealth Management, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Hohimer Wealth Management, LLC holds 159,133 shares of ACAD stock, worth $2.68 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
159,133
Previous 159,133 -0.0%
Holding current value
$2.68 Million
Previous $2.59 Million 5.26%
% of portfolio
0.54%
Previous 0.61%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

BUY
$14.62 - $18.42 $2.08 Million - $2.62 Million
142,000 Added 828.81%
159,133 $2.59 Million
Q3 2023

Nov 20, 2023

SELL
$20.84 - $33.47 $15,630 - $25,102
-750 Reduced 4.19%
17,133 $357,000
Q2 2023

Jul 27, 2023

SELL
$17.8 - $25.65 $42,399 - $61,098
-2,382 Reduced 11.75%
17,883 $428,000
Q4 2022

Feb 01, 2023

BUY
$14.2 - $18.63 $60,350 - $79,177
4,250 Added 26.54%
20,265 $322,000
Q3 2022

Nov 02, 2022

SELL
$14.11 - $18.27 $7,055 - $9,135
-500 Reduced 3.03%
16,015 $262,000
Q3 2021

Oct 18, 2021

BUY
$15.78 - $24.77 $31,244 - $49,044
1,980 Added 13.62%
16,515 $274,000
Q2 2021

Jul 12, 2021

BUY
$19.4 - $27.42 $281,979 - $398,549
14,535 New
14,535 $355,000
Q1 2021

Apr 12, 2021

SELL
$25.02 - $54.99 $96,702 - $212,536
-3,865 Closed
0 $0
Q4 2020

Jan 11, 2021

BUY
$41.04 - $56.79 $158,619 - $219,493
3,865 New
3,865 $207,000
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $231,813 - $362,805
-6,365 Closed
0 $0
Q2 2020

Jul 14, 2020

BUY
$39.26 - $52.73 $98,150 - $131,825
2,500 Added 64.68%
6,365 $309,000
Q1 2020

May 05, 2020

SELL
$31.65 - $46.87 $284,850 - $421,830
-9,000 Reduced 69.96%
3,865 $201,000
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $465,841 - $661,261
12,865 New
12,865 $550,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.73B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Hohimer Wealth Management, LLC Portfolio

Follow Hohimer Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hohimer Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hohimer Wealth Management, LLC with notifications on news.